Codexis, Inc.

Crosswalk Therapeutics, Inc.

Syntis Bio, Inc.

Adam P Silverman

Gjalt W Huisman

Jonathan Vroom

Chinping Chng

William Casey Hallows

Moulay Hicham Alaoui Ismaili

Rachel Cathleen Botham

Yu Zhu

David William Homan

Jessica P Lao

Nikki Dellas

Stephan Jenne

Joyce Liu

Kerryn McCluskie

Nikki D Kruse

Faye Loan Du

Jonathan Benjamin Asfaha

Roasa Mehmood

Subhamoy Das

The present invention provides engineered leucine decarboxylase (LDC) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered leucine decarboxylase polypeptides. In some embodiments, the engineered leucine decarboxylase polypeptides display enhanced catalytic activity, as well as reduced sensitivity to proteolysis, and/or increased tolerance to low pH environments. In some embodiments, the engineered leucine decarboxylase polypeptides are optimized to provide improved storage stability. The present invention also provides methods for the use of the compositions comprising the engineered leucine decarboxylase polypeptides for therapeutic and industrial purposes.

Engineered leucine decarboxylases

The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.

Engineered acid alpha-glucosidase variants

Growing community of inventors

San Carlos, CA, United States of America

Adam P Silverman